CD27 Activation Enhances durable Immune response in Breast Cancer Patients

Published: 2026/01/30 07:35:18

A clinical trial dating back over two decades continues to yield meaningful insights into long-term breast cancer survival. Recent research indicates that patients who participated in an experimental vaccine trial continue to survive, an uncommon outcome for those with metastatic breast cancer. This prolonged survival is linked to a robust immune response characterized by the presence of immune cells displaying the CD27 marker, sparking renewed interest in its potential for cancer immunotherapy.

Uncovering the Role of CD27 in Immune Memory

Researchers at Duke Health revisited the cases of women who participated in the original trial, led by Herbert Kim Lyerly, MD, at Duke University School of Medicine. Their findings, published in Science Immunology, reveal that these patients maintain powerful immune cells capable of recognizing their cancer even years after treatment. These immune cells consistently express the CD27 marker, a key component in establishing immunological memory – the immune system’s ability to remember and rapidly respond to previously encountered threats.

“We were stunned to see such durable immune responses so many years later,” said Zachary Hartman, PhD, associate professor in the Departments of Surgery, Integrative Immunology and Pathology at Duke University School of Medicine. “It made us ask: What if we could boost this response even more?”

Boosting Immunity with CD27 Activation in Preclinical Models

to investigate the potential of CD27 activation, the research team conducted experiments using mice. They combined a HER2-targeted vaccine (HER2 is a protein frequently enough overexpressed in breast cancer cells) with an antibody designed to activate CD27. The results were compelling: approximately 40% of mice receiving the combined treatment experienced complete tumor remission,substantially higher than the 6% remission rate observed in mice treated with the vaccine alone. Duke University News reported these promising results.

The study demonstrated that the CD27 antibody enhanced the activity of CD4+ T cells, often referred to as “helper” cells. These cells play a crucial role in orchestrating the broader immune response.

CD4+ T Cells: An Underappreciated Force in Cancer Immunity

Traditionally,cancer research has primarily focused on CD8+ “killer” T cells,responsible for directly destroying tumor cells. However, this research suggests that CD4+ T cells are equally significant. They drive lasting immune memory and bolster the function of other immune cells, like CD8+ T cells, making them more effective at fighting cancer.

adding another antibody to further support CD8+ T cell activity increased tumor rejection rates in mice to nearly 90%, highlighting the synergistic effect of targeting both CD4+ and CD8+ T cell functions.

Implications for Future Cancer Vaccine Growth

Researchers found that a single governance of the CD27 antibody, alongside the vaccine, was sufficient to produce lasting effects. This simplicity could facilitate the integration of this approach with existing cancer therapies, such as immune checkpoint inhibitors and antibody-drug conjugates. The National Institutes of Health has provided funding for this research (117 R01CA238217-01A1/02S1).

Hartman emphasizes that these findings could be a critical step towards unlocking the full potential of cancer vaccines. “We’ve known for a long time that vaccines can work against cancer, but they haven’t lived up to the hype,” he explains. “This could be a missing piece of the puzzle.”

Key Takeaways

• Patients in a decades-old breast cancer vaccine trial demonstrate exceptionally long-term survival.
• The immune response in these patients is characterized by the presence of CD27-expressing immune cells.
• Activating CD27, in combination with a cancer vaccine, significantly improves tumor control in preclinical models.
• CD4+ T cells, often overlooked, play a crucial role in establishing durable anti-tumor immunity.
• The CD27 approach shows promise for enhancing the effectiveness of existing and future cancer treatments.

This research represents a significant advancement in our understanding of cancer immunology and provides a promising avenue for developing more effective cancer vaccines and immunotherapies.Further clinical trials are needed to evaluate the safety and efficacy of CD27-targeted therapies in human patients.